Sartorius (SRT3) Stock Overview
Provides bioprocess solutions, and lab products and services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SRT3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €212.80 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.52 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -40.79% |
| Change since IPO | 734.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| SRT3 | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | n/a | 3.6% | 1.0% |
| 1Y | n/a | -8.0% | 6.1% |
Return vs Industry: Insufficient data to determine how SRT3 performed against the Swiss Life Sciences industry.
Return vs Market: Insufficient data to determine how SRT3 performed against the Swiss Market.
Price Volatility
| SRT3 volatility | |
|---|---|
| SRT3 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.1% |
Stable Share Price: SRT3's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine SRT3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 13,671 | Michael Grosse | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions.
Sartorius Aktiengesellschaft Fundamentals Summary
| SRT3 fundamental statistics | |
|---|---|
| Market cap | CHF 13.17b |
| Earnings (TTM) | CHF 141.17m |
| Revenue (TTM) | CHF 3.22b |
Is SRT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRT3 income statement (TTM) | |
|---|---|
| Revenue | €3.54b |
| Cost of Revenue | €1.90b |
| Gross Profit | €1.64b |
| Other Expenses | €1.48b |
| Earnings | €154.90m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | 2.24 |
| Gross Margin | 46.26% |
| Net Profit Margin | 4.38% |
| Debt/Equity Ratio | 105.4% |
How did SRT3 perform over the long term?
See historical performance and comparisonDividends
Does SRT3 pay a reliable dividends?
See SRT3 dividend history and benchmarks| Sartorius dividend dates | |
|---|---|
| Ex Dividend Date | Mar 27 2026 |
| Dividend Pay Date | Mar 31 2026 |
| Days until Ex dividend | 23 days |
| Days until Dividend pay date | 27 days |
Does SRT3 pay a reliable dividends?
See SRT3 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/02 15:03 |
| End of Day Share Price | 2026/03/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sartorius Aktiengesellschaft is covered by 37 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Samuel England | Berenberg |